Get the Stockscreener App
4.37
0.46%
-0.02
After Hours:
4.37
Polypid Ltd stock is traded at $4.37, with a volume of 30,397.
It is down -0.46% in the last 24 hours and up +2.34% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$4.39
Open:
$4.4
24h Volume:
30,397
Relative Volume:
0.48
Market Cap:
$83.39M
Revenue:
-
Net Income/Loss:
$-34.17M
P/E Ratio:
-1.9306
EPS:
-2.2635
Net Cash Flow:
$-47.63M
1W Performance:
+4.80%
1M Performance:
+2.34%
6M Performance:
+26.67%
1Y Performance:
+51.21%
1-Day Range:
$4.2417
$4.44
1-Week Range:
$4.08
$4.685
52-Week Range:
$2.30
$5.12
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.37 | 83.78M | 0 | -34.17M | -47.63M | -2.2635 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
PolyPid (PYPD) director discloses stock options on 17,456 shares - Stock Titan
PolyPid (PYPD) director details shares and vested stock options - Stock Titan
PolyPid (PYPD) CEO details stock and option holdings in Form 3 - Stock Titan
PolyPid (PYPD) deputy CEO discloses extensive employee stock options - Stock Titan
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - TipRanks
Is PolyPid Ltd likely to announce a buybackEarnings Growth Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
PolyPid granted $4.3M waiver from FDA for D-Plex application - TipRanks
PolyPid receives $4.3M FDA fee waiver for D-PLEX100 application - Investing.com
Polypid receives PDUFA fee waiver from FDA for D-Plex100's new drug application - marketscreener.com
$4.3M FDA fee waived for new drug to prevent surgical infections - Stock Titan
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Drop in Short Interest - MarketBeat
PolyPid Ltd Stock (ISIN: US70450B1035) Surges on Analyst Optimism: 260% Upside Forecast Signals Majo - AD HOC NEWS
Wall Street Zen Upgrades PolyPid (NASDAQ:PYPD) to Hold - MarketBeat
PolyPid at Citizens Life Sciences: Strategic Moves and Market Expansion - Investing.com India
PolyPid at Citizens Life Sciences: Strategic Moves and Market Expansion By Investing.com - Investing.com Australia
PYPD: NDA submission for D-PLEX₁₀₀ is imminent, backed by strong Phase 3 efficacy data - TradingView
How PolyPid Ltd. stock performs in stagflation2026 Short Interest & Stepwise Trade Execution Plans - Naître et grandir
PYPD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PolyPid (NASDAQ:PYPD) Downgraded by Wall Street Zen to "Sell" - MarketBeat
PYPD PE Ratio & Valuation, Is PYPD Overvalued - Intellectia AI
PolyPid Announces Participation in Upcoming Investor Conferences - Bitget
PolyPid Ltd. Auditor Raises 'Going Concern' Doubt - marketscreener.com
PolyPid Ltd. (NASDAQ:PYPD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is PolyPid Ltd. stock forming a triangle patternJuly 2025 Recap & Daily Profit Maximizing Trade Tips - mfd.ru
Does PolyPid Ltd. have high return on assetsMarket Sentiment Report & Long-Term Growth Portfolio Plans - mfd.ru
Is PolyPid Ltd. stock technically oversoldJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - mfd.ru
PYPD SEC FilingsPolypid Ltd. 10-K, 10-Q, 8-K Forms - Stock Titan
Polypid targets rolling NDA submission for D-PLEX100 by end of Q1 2026 amid advanced US partnership talks - MSN
Aug Decliners: Is PolyPid Ltd likely to announce a buyback2025 Technical Patterns & Fast Gain Swing Trade Alerts - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 44.8% in January - MarketBeat
Research Analysts Issue Forecasts for PolyPid Q1 Earnings - Defense World
HC Wainwright Predicts PolyPid's Q1 Earnings (NASDAQ:PYPD) - MarketBeat
When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit? - Yahoo Finance
PolyPid Q4 Earnings Call Highlights - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 Earnings Call Transcript - Insider Monkey
Is PolyPid Ltd. likely to announce a buybackJuly 2025 Recap & Low Risk High Win Rate Picks - mfd.ru
FY2028 Earnings Forecast for PolyPid Issued By HC Wainwright - MarketBeat
PolyPid Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
PolyPid Earnings Call Flags Big 2026 Catalyst - TipRanks
PolyPid (PYPD) Analyst Rating Reiteration by HC Wainwright | PYP - GuruFocus
PolyPid (NASDAQ:PYPD) Earns Buy Rating from HC Wainwright - MarketBeat
PolyPid (NASDAQ:PYPD) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Earnings call transcript: PolyPid’s Q4 2025 results miss EPS forecasts By Investing.com - Investing.com Australia
Earnings call transcript: PolyPid’s Q4 2025 results miss EPS forecasts - Investing.com India
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
PolyPid Ltd. Advances U.S. Partnership Talks for D-PLEX₁₀₀ Following Positive FDA Feedback and Plans Rolling NDA Review - Quiver Quantitative
PolyPid (PYPD) deepens 2025 loss while D-PLEX100 advances toward FDA NDA filing - Stock Titan
PolyPid (PYPD) Q4 2025 Earnings Call Transcript - The Globe and Mail
Preview: PolyPid's Earnings - Benzinga
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):